ALGS
ALGS
NASDAQ · Biotechnology

Aligos Therapeutics Inc

$4.07
-0.44 (-9.76%)
Financial Highlights (FY 2026)
Revenue
1.12M
Net Income
-12,391,249
Gross Margin
—
Profit Margin
-1,106.7%
Rev Growth
-46.0%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 53.4% 53.4%
Operating Margin -4,024.9% -3,622.4% -15.0% -16.8%
Profit Margin -1,106.7% -1,051.4% -16.0% -16.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.12M 2.07M 10.09M 11.15M
Gross Profit — — 5.39M 5.96M
Operating Income -45,054,623 -75,146,702 -1,517,215 -1,876,673
Net Income -12,391,249 -20,667,390 -1,613,644 -1,815,730
Gross Margin — — 53.4% 53.4%
Operating Margin -4,024.9% -3,622.4% -15.0% -16.8%
Profit Margin -1,106.7% -1,051.4% -16.0% -16.3%
Rev Growth -46.0% -46.0% -9.4% -9.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 34.2K 34.2K 3.40M 3.50M
Total Equity 12.67M 12.67M 25.89M 24.88M
D/E Ratio 0.00 0.00 0.13 0.14
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -44,587,235 -78,498,653 -2,029,249 -2,356,621
Free Cash Flow — — -1,586,727 -1,930,971